Market closed
Prothena/$PRTA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Prothena
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Ticker
$PRTA
Sector
Trading on
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
173
Website
Prothena Metrics
BasicAdvanced
$688M
Market cap
-
P/E ratio
-$2.45
EPS
0.16
Beta
-
Dividend rate
Price and volume
Market cap
$688M
Beta
0.16
52-week high
$41.55
52-week low
$12.70
Average daily volume
464K
Financial strength
Current ratio
11.524
Quick ratio
11.186
Long term debt to equity
1.662
Total debt to equity
2.151
Management effectiveness
Return on assets (TTM)
-15.66%
Return on equity (TTM)
-22.90%
Valuation
Price to revenue (TTM)
5.154
Price to book
1.29
Price to tangible book (TTM)
1.29
Price to free cash flow (TTM)
-4.431
Growth
Revenue change (TTM)
-5.41%
Earnings per share change (TTM)
73.88%
3-year revenue growth (CAGR)
-12.60%
3-year earnings per share growth (CAGR)
16.89%
What the Analysts think about Prothena
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Prothena stock.
Prothena Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Prothena Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Prothena News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Prothena stock?
Prothena (PRTA) has a market cap of $688M as of December 15, 2024.
What is the P/E ratio for Prothena stock?
The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of December 15, 2024.
Does Prothena stock pay dividends?
No, Prothena (PRTA) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Prothena dividend payment date?
Prothena (PRTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Prothena?
Prothena (PRTA) has a beta rating of 0.16. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.